D

Dynavax Technologies Corp
D

DVAX

9.79500
USD
-0.02
(-0.20%)
مغلق
حجم التداول
58,467
الربح لكل سهم
0
العائد الربحي
-
P/E
-20
حجم السوق
1,176,189,967
أصول ذات صلة
A
AEMD
-0.01600
(-3.95%)
0.38900 USD
B
BCRX
0.215
(2.07%)
10.590 USD
H
HRTX
-0.01500
(-0.81%)
1.84500 USD
L
LPCN
0.01000
(0.28%)
3.56000 USD
M
MNKD
-0.10500
(-2.49%)
4.12000 USD
S
SNDX
-0.96500
(-8.92%)
9.85000 USD
المزيد
الأخبار المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.